Claim Ledger
58% answered
Did management answer the analysts?
12 analyst questions audited, 3 evaded or deflected.
View Claim Ledger →
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Dr. Lal PathLabs delivered a strong Q4 FY26 with revenue of ₹703 crore (+16.6% YoY), driven by 12.9% sample volume growth and improving revenue per patient (₹956, +7.8% YoY). EBITDA margin at 26.6% contracted ~150bps YoY due to investments in infrastructure, R&D, and new lab openings (14 labs, 1,100+ collection centers added in FY26). PAT was impacted by a one-time labor code cost (₹30 cr) and a high base from last year's liquidation gain. Management guided for early-to-mid teens revenue growth in FY27, supported by sustained double-digit growth in Delhi NCR, recovery in Suburban business, and maturation of expanded network. EBITDA margin is expected to remain in the 27-28% range as investments continue. Key risk: potential supply chain disruption from Middle East conflict could impact reagent costs if prolonged.
Promises0 met · 3 missedRisks3 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
3 promises
Promise Tracker
0 delivered, 0 close, 3 missed.
View Promises →
Risks
3 risks
Risk Intelligence
Middle East War Impact on Reagent Supply
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Sample Volume Growth
12.9%
+12.9% YoY
Q4 FY26 sample volume growth, driven by network expansion and improved patient access.
Revenue per Patient
₹956
+7.8% YoY
Improvement due to favorable test and geographic mix, despite tier-3 expansion.
Patient Volume Growth (Annual)
5.3%
+110bps YoY
FY26 annual patient volume growth, up from 4.2% in FY25, indicating steady demand.
B2C Revenue Share
75%
N/A
B2C contribution to total revenue in FY26, driven by preventive health brand Swasthfit.
What Changed vs Last Quarter
NEW
FY27 Revenue Growth: Early-to-Mid Teens
Management expects revenue growth of 13-15% in FY27, driven by network maturation, sustained Delhi NCR growth, and Suburban recovery.
NEW
FY27 Capex: ₹100-120 crore
Capital expenditure planned for 12-15 new labs, precision lab setup, and one or two radiology centers.
UPDATED
FY27 EBITDA Margin: 27-28%
EBITDA margin expected to remain in 27-28% range as investments in labs, R&D, and infrastructure continue.
DROPPED
FY26 organic revenue growth of 11-12%
Management reiterated confidence in delivering 11-12% organic revenue growth for the full fiscal year.
DROPPED
Capex of ₹150-160 crore for FY26
Capex for FY26 expected at ₹150-160 crore, including investments in radiology centers and precision diagnostic center.
DROPPED
No price increase for next 2-3 quarters
Management stated no price increase is expected for at least 2-3 quarters after passing on GST benefits.
NEW RISK
Middle East War Impact on Reagent Supply
Prolonged conflict could disrupt supply chain for imported reagents and consumables, impacting costs and availability.
NEW RISK
Margin Pressure from Investments
Continued investment in labs, R&D, and new initiatives like SOAKA may keep margins in 27-28% range, limiting near-term expansion.
NEW RISK
Price Hike Delay
Management indicated price hike is 'a few quarters away' and dependent on market conditions, delaying potential margin tailwind.
RISK GONE
Volume growth deceleration
Patient volume growth slowed to 2.7% in Q3 due to unexpected decline in seasonal fever portfolio, raising concerns about sustained volume recovery.
RISK GONE
Franchise-led margin dilution
Analyst raised concern that revenue sharing with franchise network (over 25% in Delhi) could dilute margins; management argued operating leverage offsets it.
RISK GONE
Currency impact on reagent costs
INR depreciation may increase imported reagent costs; management has long-term contracts but may need to review pricing if dollar continues to rise.
RISK GONE
Radiology ramp-up uncertainty
Advanced radiology pilot is still early; management noted it is unlikely to be a significant contributor to topline in the next 2-3 years.
Fast read
Guidance and risk preview
Management expects revenue growth of 13-15% in FY27, driven by network maturation, sustained Delhi NCR growth, and Suburban recovery.
Prolonged conflict could disrupt supply chain for imported reagents and consumables, impacting costs and availability.
View Risks →